Suspected cyber attack hits Dr. Reddys
.jpg)
Company closes "key" plants in India, the US, Russia and Brazil as a precautionary measure.
In the early hours of last Thursday, Dr. Reddy's — one of India's leading pharmaceutical companies — was forced to shut down some of its data center services in response to a suspected cyber attack.
In a company statement, Dr. Reddy's advised that in the wake of a "detected cyber-attack" it had "isolated all data services to take preventative actions".
The company has not yet disclosed what led to the data breach or what, if any, damage has been done.
Instead, the company's Chief Information Office, Mukesh Rathi, said on Friday 22 October: “We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident.”
According to The Economic Times, Dr. Reddy's servers, which house all of the company's drug data and customer/client information, were breached between 4 am and 5 am US time.
As a result, the company decided to shut "key" plants in India, the US, Russia and Brazil as a precautionary measure.
The timing of this data breach is less than ideal; the company and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, has only just recently received approval from the Drugs Controller General of India (DCGI) to conduct an adaptive Phase II/III human clinical trial for Sputnik V vaccine in India.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.